Short answer
Amgen (AMGN) filed an 8-K current report with the SEC on April 22, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). CTO David M. Reese retires June 30, 2026 after stepping down from CTO responsibilities June 1, 2026.
Amgen 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CTO David M. Reese retires June 30, 2026 after stepping down from CTO responsibilities June 1, 2026
- Responsibilities redistributed across R&D, global markets and policy, and finance leadership
- James E. Bradner, Murdo Gordon, and Peter H. Griffith assume expanded duties
- Reese remains an Executive Vice President through June 30, 2026
- Retirement benefits payable under company plans and policies
Item EX-99.1 · Exhibit EX-99.1
- David M. Reese retiring as executive vice president and CTO effective June 30, 2026
- James Bradner becoming executive vice president, R&D, Artificial Intelligence and Data effective June 1, 2026
- Sean Bruich appointed senior vice president and CTO, strengthening AI and data leadership
- Murdo Gordon assuming oversight of Global Markets and Policy, including Medical and Commercial Operations
- Reorganization prioritizes biology, data science and AI integration across drug development and commercialization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amgen 8-K filings
Get the next AMGN 8-K as it lands
Follow AMGN for push alerts, or ask the research agent what this filing means.